Navigation Links
Cambrex Reports Second Quarter of 2011 Results
Date:8/2/2011

tion of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2010 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.   CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended June 30, 2011 and 2010(in thousands)20112010% of% ofAmountSalesAmountSalesGross Sales

$

67,484$

57,403Commissions, Allowances and Rebates523376Net Sales66,96157,027Other1,4211,190Net Revenues68,38258,217Cost of Goods Sold49,32573.1%40,28470.2%Gross Profit19,05728.2%17,93331.2%Operating ExpensesSelling, General and Administrative Expenses9,19113.6%8,18414.3%Research and Development Expenses2,5723.8%2,8414.9%Total Operating Expenses11,76317.4%11,02519.2%Operating Profit7,29410.8%6,90812.0%Other Expenses/(Income):Interest Expense, net6051,171Other (Income)/Expenses, net(282)14Equity in Losses of Partially-Owned Affiliate303-Income Before Income Taxes6,6689.9%5,72310.0%Provision for Income Taxes1,9112,057Income fro
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cambrex Reports Third Quarter 2010 Results
2. Cambrex Reports Fourth Quarter and Full Year 2009 Results
3. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
4. Cambrex Reports First Quarter 2009 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports Third Quarter 2008 Results
7. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
8. Gen-Probe Reports Financial Results for the Second Quarter of 2011
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
11. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... 16, 2015 Regis Technologies looks forward ... for Cancer Research (AACR) annual meeting. Regis will exhibit ... starting Saturday, April 18, in Philadelphia and running through ... title of the oldest and largest organization focused on ... grants, and partners with survivors to promote awareness and ...
(Date:4/16/2015)... The Council for Agricultural Science ... Borlaug CAST Communication Award goes to Dr. Channapatna ... in Alabama. Award nominees must demonstrate an ability ... the use of television, radio, or other social ... a specialist in the field of plant genetics ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2Regis Technologies Joins American Association for Cancer Research Annual Meeting 2The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2
... March 20 /PRNewswire-FirstCall/,-- Evotec AG (Frankfurt Stock Exchange: EVT) is ... on the occasion of the,publication of its fiscal year 2007 ... English., Date: Friday, March 28, 2008, Time: 10.30 ... the audio webcast and to access the presentation slides you,will ...
... for placement of skin grafts ... without staples or ... today the U.S. Food and Drug Administration (FDA),approval of ARTISS ... for use in adhering skin grafts in,adult and pediatric burn ...
... 20 NexGen,Biofuels Ltd. (OTC:NXGNF) announced today that ... have been approved for quotation on the,OTC-Bulletin Board ... development stage company that is currently seeking to,develop ... assets in,the United States., For More Information ...
Cached Biology Technology:Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients 2Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients 3
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Starting rehabilitation sooner following knee arthroplasty surgery could ... physical therapy within 24 hours of surgery can improve ... well as cut hospital stays, according to new research ... SAGE. Mindful of the trend towards discharging patients ...
... separates from Greenland, is the calving due to typical ... called the Scalable, Efficient, and Accurate Community Ice Sheet ... Ridge National Laboratory, aims to use state-of-the-art simulation to ... climate. ORNL computational Earth scientist Kate Evans leads ...
... in the world such as plague, typhoid and cholera ... common: they possess an infection apparatus which is a ... body, they develop numerous hollow-needle-shaped structures that project from ... signal substances into the host cells, which re-program the ...
Cached Biology News:Rehabilitation within a day of knee replacement pays off 2Zooming in on the weapons of Salmonella 2Zooming in on the weapons of Salmonella 3
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Biology Products: